Reunion Biotech key facts
as of Oct 2026- Developer of medical hydrogel products intended to provide new medical solutions.
- Reunion Biotech is valued at approximately $45.1M as of Oct 2026 (last reported valuation).
- It has raised $35.4M; the latest was Later Stage VC ($14.5M) in Feb 2026.
- Notable investors include Qiming Venture Partners, Proxima Ventures (China), Yunfeng Capital, Qingdao Conson Financial Holdings, Dingxin Capital — 10 tracked in total.
- Status: Privately Held (backing).
Reunion Biotech's last reported valuation, Dec 2021. Nothing priced has surfaced since.
- ·Watch Reunion Biotech: the Monday email on marks, rounds and moves
Reunion Biotech funding rounds
No funding rounds for Reunion Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Reunion Biotech valuation
Reunion Biotech's last reported valuation was $45.1 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.
Reunion Biotech investors
10 investors are on record for Reunion Biotech, including Qiming Venture Partners, Proxima Ventures (China), Yunfeng Capital and Qingdao Conson Financial Holdings.
About Reunion Biotech
Developer of medical hydrogel products intended to provide new medical solutions. The company provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolism and innovative anti-tumor drugs, enabling clients with self-developed ready-to-use PEG hydrogel materials.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- reunionbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.